Maternal Genome-Wide DNA Methylation Patterns and Congenital Heart Defects by Chowdhury, Shimul et al.
Maternal Genome-Wide DNA Methylation Patterns and
Congenital Heart Defects
Shimul Chowdhury*, Stephen W. Erickson, Stewart L. MacLeod, Mario A. Cleves, Ping Hu, Mohammad A.
Karim, Charlotte A. Hobbs
Department of Pediatrics, College of Medicine, University of Arkansas for Medical Sciences, Arkansas Children’s Hospital Research Institute, Little Rock, Arkansas, United
States of America
Abstract
The majority of congenital heart defects (CHDs) are thought to result from the interaction between multiple genetic,
epigenetic, environmental, and lifestyle factors. Epigenetic mechanisms are attractive targets in the study of complex
diseases because they may be altered by environmental factors and dietary interventions. We conducted a population
based, case-control study of genome-wide maternal DNA methylation to determine if alterations in gene-specific
methylation were associated with CHDs. Using the Illumina Infinium Human Methylation27 BeadChip, we assessed maternal
gene-specific methylation in over 27,000 CpG sites from DNA isolated from peripheral blood lymphocytes. Our study sample
included 180 mothers with non-syndromic CHD-affected pregnancies (cases) and 187 mothers with unaffected pregnancies
(controls). Using a multi-factorial statistical model, we observed differential methylation between cases and controls at
multiple CpG sites, although no CpG site reached the most stringent level of genome-wide statistical significance. The
majority of differentially methylated CpG sites were hypermethylated in cases and located within CpG islands. Gene Set
Enrichment Analysis (GSEA) revealed that the genes of interest were enriched in multiple biological processes involved in
fetal development. Associations with canonical pathways previously shown to be involved in fetal organogenesis were also
observed. We present preliminary evidence that alterations in maternal DNA methylation may be associated with CHDs. Our
results suggest that further studies involving maternal epigenetic patterns and CHDs are warranted. Multiple candidate
processes and pathways for future study have been identified.
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Introduction
Birth defects are the leading cause of infant mortality, and
congenital heart defects (CHDs) are among the most fatal of all
birth defects [1]. Multiple genes have been implicated in CHD
development [2], but for the majority of infants diagnosed with a
CHD, an established causative gene or teratogenic agent cannot
be identified [3,4]. Identification of risk factors for CHDs are
further complicated by the fact that both the maternal and fetal
genetic susceptibilities may affect the intrauterine environment
during gestation, and both may contribute to the development of
CHDs [5,6]. The complex nature of non-syndromic altered
cardiogenesis presents a significant challenge to investigators
interested in deciphering the etiology of CHDs.
Maternal folate supplementation has been shown to reduce the
risk of CHDs [7]. Folate plays a key role in multiple cellular
processes that are in increased demand during pregnancy,
including amino acid and nucleotide synthesis, as well as DNA
methylation [8]. Previous studies suggest that alterations in DNA
methylation may contribute to the development of birth defects
[9,10,11]. Multiple factors that have been shown to affect DNA
methylation patterns including diet, genotype, and environmental
exposures [10,12,13] have also been recognized as maternal
factors implicated in the modification of fetal phenotypes
[14,15,16]. Maternal genes and environmental exposures may
modify the fetus through direct interactions or through alterations
in the intrauterine environment during development [17,18].
Although alterations in maternal one-carbon plasma metabolites
indicative of a cellular hypomethylation status have been
associated with an increased risk of CHDs [19,20], a comprehen-
sive study assessing maternal genomic methylation patterns has
not yet been conducted.
To understand the mechanisms whereby gene-environment
interactions lead to complex disease, epigenetic mechanisms must
be considered [21]. DNA methylation is the best characterized
epigenetic mechanism. It involves the covalent addition of a
methyl group to the cytosine base within the context of CpG
dinucleotides. CpG methylation is involved in gene silencing,
genomic imprinting, chromosomal stability and protection against
parasitic repetitive elements in various cells and tissues [22,23].
Tightly controlled DNA methylation is essential in early fetal
development, and in regulating genomic programming [24,25].
DNA methylation patterns are tissue-specific and vary depending
on cell type [26]. However, DNA methylation patterns of DNA
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potential marker of exposure and disease [14,27].
Through the use of genome-wide DNA methylation array
technology, we sought to determine if alterations in maternal gene-
specific DNA methylation were associated with CHDs. We then
further assessed candidate genes that were differentially methyl-
ated between mothers who had CHD-affected pregnancies and
control mothers, and identified potential biological processes and
pathways of biological relevance to CHDs.
Results
Genome-wide gene-specific DNA methylation was measured in
367 participants (180 cases and 187 controls). Various lifestyle
characteristics were analyzed in our sample population to
determine if these differed between cases and controls (Table 1).
The majority of cases (61.7%) and controls (60.4%) were less than
30 years old. The study population consisted mostly of Caucasian
women. Smoking was the only selected covariate that was
significantly more prevalent in cases (30.0%) than in controls
(18.7%; P=0.015).
To illustrate the representative distribution of methylation levels
across more than 27,000 CpG sites, Figure 1A displays
histograms of b-values for four randomly selected study subjects.
In each sample, the distribution is bimodal with a high peak of
hypomethylated CpG sites and a low peak of hypermethylated
CpG sites. These individuals, therefore, have a large proportion of
CpG sites characterized by low methylation, a smaller proportion
Table 1. Selected characteristics of cases and controls.
Cases (n=180) n (%) Controls (n=187) n (%) p-value
1
Age (y)
,30 111 (61.7) 113 (60.4)
$30 69 (38.3) 74 (39.6) 0.831
Race
Caucasian 136 (75.6) 148 (79.1)
African American 32 (17.8) 22 (11.8)
Others 12 (6.7) 17 (9.1) 0.205
Smoker
Missing 0 (0.0) 1 (0.5)
No 126 (70.0) 151 (80.7)
Yes 54 (30.0) 35 (18.7) 0.015
Alcohol drinker
Missing 1 (0.6) 2 (1.1)
No 93 (51.7) 85 (45.4)
Yes 86 (47.8) 100 (53.5) 0.294
Vitamin supplementation
Missing 0 (0.0) 1 (0.5)
No 99 (55.0) 111 (59.4)
Yes 81 (45.0) 75 (40.1) 0.400
Maternal education
Missing 5 (2.8) 0 (0.0)
High school or lower 83 (46.1) 79 (42.2)
College education or higher 92 (51.1) 108 (57.8) 0.342
Household income
Missing 13 (7.2) 12 (6.4)
Less than $10,000 34 (18.9) 23 (12.3)
$10,000–$30,000 60 (33.3) 55 (29.4)
$30,000–$50,000 39 (21.7) 51 (27.3)
More than $50,000 34 (18.9) 46 (24.6) 0.137
BMI (kg/m
2)
Missing 8 (4.4) 9 (4.8)
Underweight (,18.5) 3 (1.7) 6 (3.2)
Normal (18.5–24.9) 57 (31.7) 78 (41.7)
Overweight (25.0–29.9) 44 (24.4) 34 (18.2)
Obese ($30.0) 68 (37.8) 60 (32.1) 0.118
1Fisher’s exact test for categorical variables.
doi:10.1371/journal.pone.0016506.t001
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proportion of sites in between the two peaks with moderate levels
of methylation. The distributions displayed are typical of all
subjects. The observed distribution of b-values was expected as the
array design is biased to interrogate the promoter regions of genes
within CpG islands.
Figure 1B displays histograms of b-values at selected CpG sites
across all study subjects. The four CpG sites were selected to
illustrate typical methylation patterns observed in our sample
population. Each CpG site has a typical methylation level, with a
small amount of variation between individuals. Three of the four
panels in Figure 1B show substantially skewed distributions, most
dramatically for the data massed nearest 0 or 1. We did not
observe drastic shifts in DNA methylation patterns in our sample
population at individual CpG sites.
To determine if the associations between DNA methylation and
cardiac defects were related to specific cardiac phenotypes, an
analysis stratified by cardiac phenotypes was conducted (data not
shown). Cardiac phenotypes included conotruncal, septal, and
obstructive defects. Cases that had more than one cardiac defect
type were included in all relevant strata. Among cases, 47.2% had
atrial or ventricular septal defects (n=85), 35.4% had right- and
left-sided obstructive defects (n=63), and 16.7% had conotruncal
defects (n=30). The 14 cases that did not fall within one of the
three described main defect groups were excluded from the
stratified analysis due to a small sample size. Analyses with sub-
phenotype indicator variables included in the regression model
were conducted and no statistically significant findings of sub-
phenotype-specific methylation patterns were observed. Because
gene-specific methylation patterns did not deviate significantly
between cardiac phenotypes, cases were combined for subsequent
analyses to maximize power to test our study hypotheses.
Figure 2 displays a quantile-quantile (Q-Q) plot of –log10(p-
values) for the 27,249 tests of association between gene-specific
methylation and disease status. The observed quantiles are
consistently higher than their expected values under the null
hypothesis of no disease association, providing evidence of
Figure 1. Distribution of b-values for selected subjects and CpG sites. A) The distribution of b values for 27,249 CpG sites is displayed for four
randomly selected subjects. The distribution for the four subjects is representative of the distribution for the entire sample population. B) The
distribution of b values at selected CpG sites across all 367 study subjects. The four CpG sites were selected to illustrate typical methylation patterns
observed in our sample population. Each CpG site displays skewed distributions, with a small amount of variation between individuals. Three of the
four panels show substantially skewed distributions, most dramatically for the sites massed nearest 0 or 1. We did not observe drastic shifts in DNA
methylation patterns in our sample population at individual CpG sites.
doi:10.1371/journal.pone.0016506.g001
Figure 2. Quantile-Quantile (Q-Q) plot of observed versus
expected p-values. A quantile-quantile (Q-Q) plot of –log10(p-values)
for the tests of association between gene-specific methylation and
disease status. The observed quantiles are consistently higher than their
expected values under the null hypothesis of no disease association,
providing evidence of site-specific disease association for a large
number of CpG sites.
doi:10.1371/journal.pone.0016506.g002
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sites.
We identified 425 CpG sites that were differentially methylated
between cases and controls with P,0.005, although an FDR
threshold of 0.05 was not reached for any single CpG site (Table
S1). The top 50 CpG sites ranked by statistical significance are
listed in Table 2. The 425 CpG sites of interest encompassed 415
genes. The vast majority of these CpG sites were located within
CpG islands (386 CpG sites, 90.8%). Given that the array platform
contains 76% of sites within CpG islands, this result was
statistically significant (P,0.001). Additionally, we observed that
case mothers were hypermethylated in the majority of loci (379
sites, 89.2%) compared to hypomethylated loci (46 sites, 10.8%).
Finally, the list of differentially methylated genes includes four
genes previous shown to be imprinted (Table 3) as well as 14
miRNA sites (Table 4).
Further analysis of the differentially methylated genes was
conducted for potential biological significance. Gene Set Enrich-
ment Analysis (GSEA) was performed to determine if the
differentially methylated genes were significantly enriched in
relevant biological processes and pathways of biological relevance
to fetal heart development.
The 415 genes of interest were input into the GSEA program,
and the top ten gene set overlaps were generated. Figure 3A
summarizes the results of the most significant overlaps for the
biological process analysis. Within the top ten most significant
gene set overlaps, multiple functional categories associated with
development were strongly enriched within our differentially
methylated gene list. Specifically, the biological process categories
of nucleic acid metabolism, signal transduction, anatomical
structure development, multicellular organismal development,
and system development have potential direct functional implica-
tions in the development of CHDs. The inclusion of these specific
processes within the top ten most significant gene set overlaps
provided evidence of strong biological relevance of the differen-
tially methylated genes to fetal development. GSEA was also
conducted to determine if significant canonical pathway overlaps
could be established from the differentially methylated gene list
(Figure 3B). Pathway analysis revealed functional overlaps that
have previously been shown to be involved in embryonic heart
development. These pathways included cytokine-cytokine receptor
interaction, the regulation of actin cytoskeleton, tight junction,
calcium signaling pathway, smooth muscle contraction and the
Wnt signaling pathway. The GSEA results provided further
evidence that the genes that were found to be differentially
methylated appear to have biological relevance to CHDs. The
results summaries generated from the GSEA, which includes the
specific differentially methylated genes involved within each
biological process and canonical pathway overlap, is included in
Table S2 and Table S3 respectively.
Discussion
To our knowledge, we have performed the first population
based maternal case-control study to provide evidence of
association between maternal gene-specific DNA methylation
and CHDs. Further analysis of the differentially methylated genes
revealed functionally relevant enrichment in biological processes
and pathways previously shown to be involved in fetal develop-
ment.
No individual CpG site achieved genome-wide statistical
significance. A combination of low variation in site-specific
methylation between individuals and relatively modest sample
size may account for the inability to reach statistical genome-wide
significance. Thus, caution in interpreting the results of differen-
tially methylated genes of interest must be noted. The advent of
genome-wide association studies (GWAS) has led to an influx of
studies structured to detect genetic variants associated with various
human diseases, but limited studies have been conducted using
genome-wide DNA methylation platforms. Issues regarding
adjustments for multiple testing, statistically significant thresholds,
and biologically relevant alteration levels, have not been
established for high-throughput DNA methylation studies. The
increased demand for genome wide epigenetic studies will lead to
clearer definition of these issues in the future.
In the current study, gene-specific methylation was measured in
DNA isolated from peripheral blood lymphocytes. We observed
slight alterations in methylation between cases and controls.
Factors such as genetic variation, metabolites involved in one-
carbon metabolism, and environmental exposures are possible
mechanisms of differential methylation between cases and
controls. The interpretation of results from DNA methylation
studies must always be evaluated with caution as epigenetic marks
may vary depending on cell type and can be influenced by various
factors. Previous studies have used Illumina Infinium technology
to assess DNA methylation in peripheral blood lymphocytes and
have identified CpG sites associated with disease [27,28]. The
accumulation of studies that have assessed DNA methylation
patterns in lymphocytes in multiple diseases and exposures
provides evidence that methylation patterns in peripheral blood
cells may be useful in identifying biomarkers of various diseases.
It has been established that various maternal factors may cause
altered fetal growth and development [29], but the impact of
maternal genetics and epigenetics in the development of birth
defects is not well understood. Maternal genes may exert effects
through direct interactions with the fetus [30,31] or through
changes to the intrauterine environment. Maternal blood provides
nutrients to the developing fetus and could provide an avenue of
signal exchange. Multiple studies have been conducted to
determine the impact of maternal genetic effects and the risk of
birth defects [32,33,34]. Although these studies encompass a
relatively small number of genes with respect to the genome, they
suggest that maternal genetic effects, independent of fetal
genotype, may influence the risk of birth defects. Additionally,
alterations in gene expression in maternal blood are associated
with adverse pregnancy outcomes [35,36] providing further
evidence that maternal genetic influence may impact the fetus.
Epigenetics are considered to be the link between environmental
exposures and their effects on the genome [37] and may explain
how maternal genes may exert effects on the developing fetus.
Genes previously implicated in CHDs were identified within our
differentially methylated genes. For example, multiple genes
involved in the mitogen-activated protein kinases (MAPK)
pathway are included in the list of differentially methylated genes.
The MAPK pathway is involved in multiple cellular processes
including transcription, proliferation, migration, survival, and
differentiation [38]. It has been postulated that this family of genes
may play a role in CHDs [39]. Additional genes implicated in
heart development that were differentially methylated in our study
include, but are not exclusive to, EGFR [40], GATA4 [41], and
Wnt5a [42]. The inclusion of multiple miRNA targets as candidate
genes is intriguing as the diverse role of miRNAs in cardiac
function has received increased interest [43]. Although genetic
studies have been conducted on these genes of interest, our results
indicate that epigenetics should be considered as well.
Alterations in maternal DNA methylation may also indirectly
affect the fetus through changes in the maternal environment.
Changes in the maternal environment can result in direct changes
Maternal Methylation and Congenital Heart Defects
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SYMBOL Gene name Gene_ID p-value
1 q-value
2 Chr
3
CpG
Island Direction
4
CTSL2 cathepsin L2 1515 1.6E-05 0.13378 9 Yes +
RREB1 ras responsive element binding protein 1 6239 1.6E-05 0.13378 6 Yes +
BSN bassoon (presynaptic cytomatrix protein) 8927 2.2E-05 0.13378 3 Yes +
HSPC268 hypothetical protein HSPC268 154791 4.6E-05 0.17086 7 Yes +
NEUROG1 neurogenin 1 4762 5.5E-05 0.17086 5 Yes +
MAP4K5 mitogen-activated protein kinase kinase kinase kinase 5 11183 7.3E-05 0.17086 14 Yes +
FTMT ferritin mitochondrial 94033 7.4E-05 0.17086 5 Yes -
CPE carboxypeptidase E 1363 8.8E-05 0.17086 4 Yes +
EXT2 exostosin 2 2132 0.0001 0.17086 11 Yes +
UBE3A ubiquitin protein ligase E3A 7337 0.00013 0.17086 15 Yes +
DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 10049 0.00014 0.17086 7 Yes +
UQCRH ubiquinol-cytochrome c reductase hinge protein 7388 0.00014 0.17086 1 Yes +
ORF1-FL49 chromosome 5 open reading frame 32 84418 0.00016 0.17086 5 Yes +
H2AFY2 H2A histone family, member Y2 55506 0.00018 0.17086 10 Yes +
PKN2 protein kinase N2 5586 0.00022 0.17086 1 Yes +
STRN3 striatin, calmodulin binding protein 3 29966 0.00022 0.17086 14 Yes +
C8orf35 chromosome 8 open reading frame 35 55174 0.00022 0.17086 8 Yes +
NDUFA7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 4701 0.00023 0.17086 19 Yes -
SLC36A4 solute carrier family 36 (proton/amino acid symporter), member 4 120103 0.00023 0.17086 11 Yes +
C6orf72 chromosome 6 open reading frame 72 116254 0.00023 0.17086 6 Yes +
C6orf199 chromosome 6 open reading frame 199 221264 0.00025 0.17086 6 Yes +
CCDC74A coiled-coil domain containing 74A 90557 0.00026 0.17086 2 Yes +
TERF1 telomeric repeat binding factor (NIMA-interacting) 1 7013 0.00028 0.17086 8 Yes +
SNX3 sorting nexin 3 8724 0.00028 0.17086 6 Yes +
HNRPH3 heterogeneous nuclear ribonucleoprotein H3 (2H9) 3189 0.0003 0.17086 10 Yes +
CGNL1 cingulin-like 1 84952 0.00031 0.17086 15 Yes -
ITM2B integral membrane protein 2B 9445 0.00031 0.17086 13 Yes +
ZNF544 zinc finger protein 544 27300 0.00032 0.17086 19 Yes +
MGC14376 hypothetical protein MGC14376 84981 0.00035 0.17086 17 Yes +
ICAM3 intercellular adhesion molecule 3 3385 0.00036 0.17086 19 No +
RRP22 Ras-related protein 22 10633 0.00036 0.17086 22 Yes +
AGTPBP1 ATP/GTP binding protein 1 23287 0.00037 0.17086 9 Yes +
WNT5A wingless-type MMTV integration site family, member 5A 7474 0.00037 0.17086 3 Yes +
GMDS GDP-mannose 4,6-dehydratase 2762 0.00039 0.17086 6 Yes +
XPR1 xenotropic and polytropic retrovirus receptor 1 9213 0.0004 0.17086 1 Yes +
GDF3 growth differentiation factor 3 9573 0.00041 0.17086 12 Yes +
RASEF RAS and EF-hand domain containing 158158 0.00041 0.17086 9 Yes +
KCTD4 potassium channel tetramerisation domain containing 4 386618 0.00041 0.17086 13 No -
RFXAP regulatory factor X-associated protein 5994 0.00041 0.17086 13 Yes +
KCNA4 potassium voltage-gated channel, shaker-related subfamily, member 4 3739 0.00042 0.17086 11 Yes +
EGFR epidermal growth factor receptor 1956 0.00043 0.17086 7 Yes +
LGR6 leucine-rich repeat-containing G protein-coupled receptor 6 59352 0.00045 0.17086 1 Yes +
MAPK13 mitogen-activated protein kinase 13 5603 0.00047 0.17086 6 Yes +
SSFA2 sperm specific antigen 2 6744 0.00049 0.17086 2 Yes +
PHCA phytoceramidase, alkaline 55331 0.00049 0.17086 11 Yes +
TBC1D1 TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1 23216 0.00049 0.17086 4 Yes +
LRRC3B leucine rich repeat containing 3B 116135 0.00049 0.17086 3 Yes +
SHCBP1 SHC SH2-domain binding protein 1 79801 0.0005 0.17086 16 Yes +
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harmful exposures occur during organogenesis, various structural
anomalies may occur [13]. Alterations in maternal methylation in
genes involved in the maintenance of the intrauterine environment
may lead to an increased susceptibility to teratogenic agents.
Genes that were found to be differentially methylated, such as
GPX3, provide an example of a gene involved in the sustainment
of a normal maternal environment. The GPX3 gene is involved in
antioxidant potential in the body. Altered expression in GPX3 may
result in a lower anti-oxidant potential, which may potentially lead
to increased oxidative stress for the fetus.
It is though that hypomethylation in the parental germline can
influence genomic instability, and that this instability may
subsequentlycausegenomicinstabilityintheprogeny[45].Although
itisunclearhowmaternallymphocytemethylationpatternscorrelate
with germ cells or the fertilized oocyte, maternal methylation
patterns in peripheral blood DNA have recently been shown to
correlate with infant methylation patterns in certain loci [46,47].
The phenomenon of passing intact methylation patterns to future
generations, termed transgenerational epigenetic inheritance, has
beenusedtoexplainnon-Mendelianinheritancepatternsincomplex
diseases. Although speculation regarding whether epigenetic marks
are transmitted intact from parent to offspring exists [48], the vast
majority of the evidence is found in animal models [49].
The importance of epigenetic factors in the development of
complex disease is now unquestioned. Embryonic heart develop-
ment requires a series of highly complex, coordinated and rapid
morphogenesis processes. Specifically for CHDs, epigenetic factors
may contribute to cardiomyocyte differentiation and chamber
morphogenesis [50], and it has been proposed that epigenetic
mechanisms are necessary to coordinate genetic programs in heart
development [51]. The complex series of events involved in heart
development indicates that multiple genes and pathways are
responsible for CHDs [52]. Although many studies have been
conducted to investigate the developmental genetics of CHDs,
limited studies are available regarding DNA methylation within
these genes and pathways. Our analysis of biological processes
revealed overlaps involving system, anatomical structure, and
organismal development. The listed processes are involved in fetal
development and provide candidate processes for additional
epigenetic studies. Nucleic acid metabolism and signal transduc-
tion are also of importance to development as the increase demand
for DNA synthesis and properly functioning signaling cascades are
important during pregnancy [8,53]. Canonical pathways enriched
within our genes of interest have previously been implicated in
heart development and some of the pathways appear to be
interconnected. For example, alterations in intracellular calcium
levels can affect smooth muscle contraction downstream [54].
Other significant pathways that have previously been implicated in
heart development include ribosomal proteins [55], the actin
cytoskeleton [52], Wnt signaling [56], and cytokine-cytokine
receptor interaction [57]. Future epigenetic studies should be
conducted within the candidate pathways and processes described.
Certain methodological limitations of this study should be
considered. The blood obtained to isolate genomic DNA was
collected after pregnancy. We have previously described the
rationale for the use of case-control study designs in human birth
defects research studies [20]. We did not measure DNA
methylation changes during gestation and neonatal development,
which represents a period of high epigenomic susceptibility [58].
Contrasting reports exist regarding gene-specific methylation
changes over time [59,60], and it is unclear how maternal
methylation patterns may change during pregnancy. Another
limitation of our study is the lack of infant methylation data to
determine if differential methylation is observed between infants
with CHDs and controls, and if these methylation patterns are
associated with maternal DNA methylation patterns. Previous
studies have shown global DNA hypomethylation in the proband
for neural tube defects [61,62], but studies in gene-specific and
global methylation in a family-based design should be conducted
for other congenital anomalies including CHDs. The design of the
HumanMethylation27 BeadChip allows the assessment of over
SYMBOL Gene name Gene_ID p-value
1 q-value
2 Chr
3
CpG
Island Direction
4
PMS2 PMS2 postmeiotic segregation increased 2 (S. cerevisiae) 5395 0.00053 0.17086 7 Yes +
ZNF304 zinc finger protein 304 57343 0.00053 0.17086 19 Yes +
1p-values were calculated by multiple linear regression and randomization testing (see Materials and Methods).
2q-values were calculated using the qvalue package in the R statistical programming environment under default settings (see Materials and Methods).
3Chr= chromosome.
4Direction of methylation in cases.
doi:10.1371/journal.pone.0016506.t002
Table 2. Cont.
Table 3. Differentially methylated imprinted genes.
SYMBOL Gene function p-value
1 q-value
2 Direction of methylation in cases Chromosome CpG Island
UBE3A Imprinted 0.0001262 0.1708606 + 15 Yes
ZNF264 Imprinted 0.0008294 0.1743975 + 19 Yes
SNURF Imprinted 0.0039526 0.1822456 - 15 Yes
INS Imprinted 0.0043908 0.1822456 - 11 No
1p-values were calculated by multiple linear regression and randomization testing (see Materials and Methods).
2q-values were calculated using the qvalue package in the R statistical programming environment under default settings (see Materials and Methods).
doi:10.1371/journal.pone.0016506.t003
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genome [48]. The assay is focused primarily on one or two CpG
sites within gene promoter regions. Thus, most of the neighboring
CpG sites are not studied. Although our study has revealed a
strong bias in DNA alterations occurring in CpG islands, the
possibly exists for DNA methylation alterations occurring outside
CpG islands and in CpG sites not included on the assay. Although
the Illumina Infinium HumanMethylation27 platform provides a
high-throughput and a reliable examination of a large number of
genes [63], studies in birth defects investigating a larger number of
CpG sites should be conducted. Our study provides additional
evidence that maternal epigenetics and genetics should be
included in the investigation of birth defects.
Alterations in maternal DNA methylation converge with
evidence from previous studies that indicate folate-dependent
genetic and metabolic susceptibilities increase the risk of CHDs.
The study has notable strengths including analyzing genome-wide
gene specific DNA methylation in a large population of mothers.
Figure 3. Gene Set Enrichment Analysis (GSEA) of biological processes and canonical pathways for differentially methylated genes.
A) The top ten significantly enriched biological processes are displayed with their corresponding –log10(p-value). Multiple processes appear to be
directly related to fetal heart development. B) The top ten significantly enriched canonical pathways are displayed with the corresponding 2log10(p-
value). Multiple pathways had previously been implicated in CHDs.
doi:10.1371/journal.pone.0016506.g003
Table 4. Differentially methylated miRNAs.
Gene miRNA p-value
1 q-value
2 Direction of methylation in cases Chromosome CpG Island
HOXB4 HSA-MIR-10A; 0.0043384 0.1822456 + 17 Yes
BTG4 HSA-MIR-34B;HSA-MIR-34C; 0.0006663 0.1708606 + 11 Yes
CCDC55 HSA-MIR-423; 0.0029542 0.1822456 - 17 Yes
SACM1L HSA-MIR-565; 0.0008043 0.1743975 + 3Y e s
HSPC268 HSA-MIR-594; 0.0000463 0.1708606 + 7Y e s
HSPC268 HSA-MIR-594; 0.0045767 0.1822456 + 7Y e s
WDR37 HS_104; 0.0033306 0.1822456 + 10 Yes
DUSP4 HS_128; 0.0034043 0.1822456 + 8Y e s
C10orf4 HS_138; 0.0026144 0.1822456 + 10 Yes
PIGO HS_140; 0.0044543 0.1822456 + 9Y e s
PPME1 HS_176; 0.0015582 0.1822456 + 11 Yes
DUS2L HS_253;HS_253; 0.0041322 0.1822456 - 16 Yes
CDC7 HS_255; 0.0049322 0.1822456 + 1Y e s
FBXO28 HS_78; 0.0015055 0.1822456 + 1Y e s
1p-values were calculated by multiple linear regression model and randomization testing (see Materials and Methods).
2q-values were calculated using the qvalue package in the R statistical programming environment under default settings (see Materials and Methods).
doi:10.1371/journal.pone.0016506.t004
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experimental confounders. We also adjusted for various lifestyle
factors that have been shown to affect DNA methylation. The data
presented here strongly suggest that maternal epigenetics may be a
determinant of CHD risk. The non-invasive nature of the
determination of DNA methylation in lymphocytes isolated from
peripheral blood draw makes it an attractive candidate for disease
risk assessment. Identification of genetic and epigenetic profiles
associated with an increased risk of CHDs may add new
dimensions to preconception risk assessment as well as further
elucidate mechanisms involved in CHD development. Because
DNA methylation may be influenced by diet or drugs, epigenetics
may provide an avenue for future therapeutic intervention and
prevention of CHDs.
Materials and Methods
Study Population
The National Birth Defects Research and Prevention Study
(NBDPS) is an ongoing multi-site population-based case-control
study investigating the etiology of 30 non-syndromic birth defects
[64]. The NBDPS is the largest case-control study of birth defects
ever conducted in the US. The study population and eligibility
criteria for the NBDPS have been previously outlined [20]. For the
current study, case women were Arkansas residents who
participated in the NBDPS and who delivered a singleton live
birth with a non-syndromic CHD. Cases for whom the pregnancy
was also affected by a known single gene disorder, chromosomal
abnormality, or syndrome were excluded. All diagnostic tests on
cardiac NBDPS case infants were reviewed by a pediatric
cardiologist to ensure uniform criteria were used for diagnoses.
To be eligible for the study described, case infants were required to
have at least one cardiac lesion, which included conotruncal,
septal, and/or obstructive lesions. Using a classification system
developed for the NBDPS, which incorporated three dimensions
of cardiac phenotype, cardiac complexity, and extracardiac
anomalies [65], case women for the current study included those
who carried fetuses with simple or association CHDs. Control
mothers were Arkansas residents who had a singleton live birth
without birth defects during the same period as the cases, who
participated in the NBDPS, and were randomly selected from
birth certificate data or hospital discharge logs. Case and control
mothers spoke either English or Spanish.
From eligible Arkansas NBDPS participants, we assessed DNA
methylation in 180 cases and 187 controls for whom frozen blood
samples were available. Blood samples were collected by research
nurses during home visits in Arkansas that occurred between 2001
and 2008. Samples were collected by venipuncture after
pregnancy. All participants signed informed consent approved
by the UAMS Institutional Review Board.
Covariates
Information regarding selected lifestyle factors was obtained from in-
home interviews conducted by research nurses using a Block
Abbreviated Food-Frequency Questionnaire [66] and from a
NBDPS-structured computer-assisted telephone interview. The infor-
mation on covariates reflects data up to one month prior to the visit.
V a r i a b l e sc o n s i d e r e da sc o v a r i a t e si nt h i ss t u d yd u et ot h e i rp o t e n t i a l
effects on DNA methylation status were age, race, body mass index
(BMI), and the use of multivitamins, cigarettes, and alcohol.
Sample preparation and processing
Fasting blood samples were collected in EDTA-Vacutainer
tubes and immediately chilled on ice before they were centrifuged
at 40006g for 10 min at 4uC. DNA was isolated from the stored
frozen blood samples according the manufacturer’s protocol for
the PureGene DNA isolation kit (Gentra Systems, Minneapolis, MN).
DNA quantification and bisulfite conversion
Genomic DNA was quantified via the RNase P 20x assay
(Applied Biosystems, Forest City, CA). In a total reaction volume of
25 ml, 2 ml of genomic DNA was used for absolute quantification
for the RNase P assay on the ABI 7900HT Real Time PCR
System, according to the manufacturer’s protocol. After genomic
DNA quantification, 500 ng of genomic DNA underwent bisulfite
modification utilizing the EZ DNA Methylation-Direct Kit (Zymo
Research, Orange, CA). The bisulfite-converted DNA was resus-
pended in 12 ml TE buffer and stored at -80uC until the samples
were ready for analysis.
Infinium Assay for Methylation
DNA methylation analysis was conducted using the Illumina
Infinium Human Methylation27 BeadChip. Each HumanMethy-
lation27 BeadChip consists of 12 arrays, and up to 4 bead chips
were processed simultaneously. The assay allows the interrogation
of over 27,000 CpG sites located within the proximal promoter
regions of over 14,000 consensus coding sequences (CCDS) genes
throughout the genome [63]. In addition, the assay includes 110
miRNA promoters and also includes imprinted genes.
The standard protocol provided by Illumina was used for DNA
methylation analysis. Briefly, 4 ml of bisulfite converted DNA was
isothermally amplified at 37uC overnight. The amplified DNA
product was fragmented by an endpoint enzymatic process.
Fragmented DNA was precipitated, resuspended, and applied to
an Infinium Human Methylation27 BeadChip and hybridized
overnight. During hybridization, the amplified and fragmented
DNA samples anneal to specific oligomers that are covalently
linked to over 27,000 different bead types. Each bead type
corresponds to the nucleotide identity and thus the methylation
status at a bisulfite-converted cytosine in a specific CpG site. The
bead chips were then subjected to a single-base extension reaction
using the hybridized DNA as a template incorporating fluores-
cently labeled nucleotides of two different colors, each corre-
sponding to the cytosine (methylated) or uracil (unmethylated)
identity of the bisulfite-converted nucleotide at a specific CpG site.
The fluorescently stained chip was imaged by the Illumina
BeadArray Reader. Illumina’s Genome Studio program was used
to analyze BeadArray data to assign site-specific DNA methylation
b-values to each CpG site. The proportion of methylation (b) for
each subject at each CpG site was computed by first subtracting
the background signal intensity of negative controls from both the
methylated and unmethylated signals and then taking the ratio of
the methylated signal intensity to the sum of both methylated and
unmethylated signals. Thus, the b-value is a continuous variable
ranging between 0 and 1.
Experimental Design and Quality Control
A total of one batch of two bead chips (24 samples) and eight
batches of four bead chips were assayed. Cases and controls were
randomly placed within the bead chips. Replicate samples were
included in each batch for quality control and normalization
measures. All replicate samples achieved a correlation coefficient
of greater than 0.985 (data not shown). Using Illumina’s Genome
Studio, background adjusted b-values and assay control probe
information was used for initial quality control. Subjects were
required to pass three initial quality control criteria in order to be
included in further analysis: 1) Subjects achieved a 95% CpG site
call rate, which equals 26,250 sites called at an a,0.05
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1000 units, determined from the controls dashboard in Genome
Studio; and 3) Clear separation was observed in the non-
polymorphic controls, also determined from the controls dash-
board. Samples that did not meet these criteria were removed
from the analysis. Individual CpG sites were examined using the
detection p-value metric provided by Illumina in which the signal
generated from each CpG site is compared to negative controls. A
threshold of p,0.05 was used as a cutoff. CpG sites that did not
reach this threshold were eliminated from the analysis. Using this
criterion, 329 of 27,578 CpG sites (1.2%) had missing or invalid b-
values in ten or more samples; these sites were dropped from
subsequent analysis, leaving 27,249 CpG sites among 367 subjects.
Principal Component Analysis
Principal component analysis (PCA) was performed on the b-
value data matrix of 367 subjects (rows) and 27,249 CpG sites
(columns). Data were logit-transformed prior to PCA and
subsequent association testing. As described above, 329 CpG sites
with missing or invalid b-values in ten or more samples were
removed from the data; before performing PCA, any remaining
missing b-values were imputed using k nearest neighbor averaging
[67].
The first 20 principal components (PCs) explain 62.8% of
overall variance in the logit-transformed b-value matrix, and no
single PC among the remaining 347 PCs explains more than
0.34% (Figure S1). Regression analysis (not shown) revealed that
these 20 PCs are variously associated with experimental factors
that had been previously shown to be potential confounders under
the Infinium Methylation platform [27], as well as with several
phenotypic and lifestyle factors, including case/control status, age,
race, and body mass index (BMI), and the use of multivitamins,
cigarettes, and alcohol. Regression analysis of the top 20 PCs
therefore informed the selection of covariates to be included in the
CpG-site-specific regression model, which is described in the
following section.
Determination of differentially methylated sites between
cases and controls
After initial quality control and PCA of the b value data, a
sample of 367 subjects (180 cases and 187 controls) was tested for
association between disease status (i.e. case/control) and maternal
gene-specific methylation. In this analysis, each CpG site was
tested for association by regressing its logit-transformed b value on
case/control status using multiple linear regression models.
Additional covariates included these models were experimental
batch (as a factor), bisulfite-conversion (BSC) efficiency, age, BMI,
race (as a factor), and indicator variables of perinatal vitamin
usage, alcohol drinking, and tobacco smoking. BSC efficiency for
each subject has two channels, red and green. The red and green
channels are highly correlated but are not sufficiently to be
collinear, thus both channels were included in the models (Figure
S2).
Under standard theory a t-statistic, derived from the least-
squares estimate of the case/control parameter and its standard
error, was compared with the theoretical t-distribution to test the
null hypothesis of no association between disease status and site-
specific methylation, H0 : cj~0, where j =1,…,27,249 indicates
the CpG site. Because of the potential for spurious association due
to chip bias, however, a randomization testing approach was used
to evaluate statistical significance. For each pseudo-dataset, disease
status was randomized in a two-stage process for each chip. First,
disease status was randomly permuted among the subjects on that
chip, and then with 50% probability, disease status was swapped
between case and control for all subjects on the chip.
In each pseudo-dataset, therefore, each subject was equally
likely to be assigned case or control status, which means that,
H0 : cj~0 is known to be (synthetically) true. However, because
the randomization is performed separately within chips, the
structure of the experimental design, and therefore the chance for
spurious disease association due to chip effect, is retained. The
empirical null distributions resulting from this randomization
approach had heavier tails than the theoretical null distribution,
leading to less significant p-values. The randomization approach is
therefore a conservative approach and properly controls type-I
error in the presence of chip-to-chip variation of b-values.
To properly account for the large number of statistical tests
being performed, false discovery rate (FDR) q-values [68] were
computed for each CpG site. In our context, FDR is the
proportion of detected disease associations (under a given
hypothesis testing procedure) that are false, while the q-value is
defined as the minimum FDR at which a given test can be
considered significant. The q-value is therefore the FDR
equivalent of the p-value and was computed using the qvalue
package in the R statistical programming environment, under
default settings [69].
Biological Processes and Pathway Analysis
Based on the results from our association testing, a list of
differentially methylated CpG sites with p-values less than 0.005
was generated. The CpG sites of interest were to mapped to their
corresponding genes and the list of genes were then tested for
potential overlaps with biological processes and pathways using the
Gene Set Enrichment Analysis (GSEA) [70]. The software is
designed to evaluate microarrays at the level of gene sets. Gene
sets are defined as groups of genes that share common biological
function, chromosomal location or regulation. The gene set
database used in the analysis is established based on prior
biological knowledge.
Supporting Information
Figure S1 Variance explained by first 20 (of 367)
principal components. The proportion of variance explained
by each of the first 20 of 367 principal components, from a PCA of
the 367-by-27,249 matrix of logit-transformed methylation b-
values. Combined, the first 20 PCs explain 62.8% of overall
variance, with no single PC among the remaining 347 explaining
more than 0.34%.
(PDF)
Figure S2 Bisulfite conversion efficiency metrics scat-
terplot. Scatterplot of the red and green channels of bisulfite
conversion efficiency for the 367 samples used in association
testing, overlaid with a locally weighted scatterplot smoothing
(LOWESS) curve.
(PDF)
Table S1 List of differentially methylated CpG sites at
P,0.005.
(DOC)
Table S2 Gene Set Enrichment Analysis for Biological
Processes.
(XML)
Table S3 Gene Set Enrichment Analysis for Canonical
Pathways.
(XML)
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